openPR Logo
Press release

Investigation announced for Investors in shares of Xeris Pharmaceuticals, Inc. (NASDAQ: XERS)

03-16-2021 06:43 PM CET | Business, Economy, Finances, Banking & Insurance

Press release from: Shareholders Foundation

An investigation for investors in Xeris Pharmaceuticals, Inc. (NASDAQ: XERS) shares over potential securities laws violations.

An investigation for investors in Xeris Pharmaceuticals, Inc. (NASDAQ: XERS) shares over potential securities laws violations.

An investigation was announced concerning possible violations of securities laws by Xeris Pharmaceuticals, Inc. in connection with certain financial statements.

Investors who purchased shares of Xeris Pharmaceuticals, Inc. (NASDAQ: XERS), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

The investigation by a law firm focuses on whether a series of statements by Xeris Pharmaceuticals, Inc. regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

Chicago, IL based Xeris Pharmaceuticals, Inc., a specialty pharmaceutical company, develops and commercializes ready-to-use injectable and infusible drug formulations.

On or around June 20, 2018, Xeris conducted its initial public offering ("IPO"), selling 5,700,000 shares of common stock priced at $15.00 per share.

On March 9, 2021, Xeris Pharmaceuticals, Inc announced its fourth quarter and full year 2020 results. Xeris Pharmaceuticals, Inc. reported that its annual Total Revneue rose from $2.72 million in 2019 to $20.15 million in 2020, and that its Net Loss declined from $125.58 million in 2019 to $91.13 million in 2020. However, Xeris Pharmaceuticals, Inc reported fourth quarter GAAP earnings per share of $0.41, missing consensus estimates by $0.01, and revenue of $7.09 million, missing consensus estimates by $1.82 million.

Shares of Xeris Pharmaceuticals, Inc. (NASDAQ: XERS) declined to $3.98 per share on March 9, 2021.

Those who purchased shares of Xeris Pharmaceuticals, Inc. (NASDAQ: XERS) have certain options and should contact the Shareholders Foundation.

Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com

About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Investigation announced for Investors in shares of Xeris Pharmaceuticals, Inc. (NASDAQ: XERS) here

News-ID: 2257314 • Views: 416

More Releases from Shareholders Foundation

Lawsuit filed for Investors in shares of CytoDyn Inc. (OTC: CYDY)
An investor, who purchased shares of CytoDyn Inc. (OTC: CYDY), filed a lawsuit over alleged violations of Federal Securities Laws by CytoDyn Inc. in connection with certain allegedly false and misleading statements. Investors who purchased shares of CytoDyn Inc. (OTC: CYDY) have certain options and for certain investors are short and strict deadlines running. Deadline: May 17, 2021. OTC: CYDY investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858)
Investigation announced for Long-Term Investors in shares of SolarWinds Corporat …
An investigation on was announced concerning potential breaches of fiduciary duties by certain directors and officers of SolarWinds Corporation. Investors who are current long term investors in SolarWinds Corporation (NYSE: SWI) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm for current long term investors in NYSE: SWI stocks follows a lawsuit filed against SolarWinds Corporation
Update in Lawsuit for Investors in shares of Merit Medical Systems, Inc. (NYSE: …
An investor in Merit Medical Systems, Inc. (NYSE: MMSI) shares filed a lawsuit in December 2019, against Merit Medical Systems, Inc. over alleged violations of Federal Securities Laws. Investors who purchased shares of Merit Medical Systems, Inc. (NYSE: MMSI) prior to February 2019 and continue to hold any of those shares, have also certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. After the market
Deadline on May 3rd coming up in Lawsuit for Investors in Velodyne Lidar, Inc. ( …
A deadline is coming up on May 3, 2021 in the lawsuit filed for certain investors of Velodyne Lidar, Inc. (NASDAQ: VLDR) over alleged securities laws violations by Velodyne Lidar, Inc. Investors who purchased shares of Velodyne Lidar, Inc. (NASDAQ: VLDR) have certain options and there are strict and short deadlines running. Deadline: May 3, 2021. NASDAQ: VLDR stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 -

All 5 Releases


More Releases for Xeris

The subcutaneous biologic drugs and affiliated technologies market is projected …
Subcutaneous drug delivery, given the use of tailored formulation development solutions, has brought about a paradigm shift in at-home healthcare, enabling users to administer (life-saving) medications without having to rely on medical professionals Roots Analysis is pleased to announce the publication of its recent study, titled “Subcutaneous Biologics, Technologies and Drug Delivery Systems (3rd Edition), 2020-2030” report to its list of offerings. For additional details, please visit https://www.rootsanalysis.com/reports/view_document/subcutaneous-biologics-delivery/314.html The report provides
The subcutaneous biologic drugs and affiliated technologies market is projected …
Subcutaneous drug delivery, given the use of tailored formulation development solutions, has brought about a paradigm shift in at-home healthcare, enabling users to administer (life-saving) medications without having to rely on medical professionals Roots Analysis is pleased to announce the publication of its recent study, titled “Subcutaneous Biologics, Technologies and Drug Delivery Systems (3rd Edition), 2020-2030” report to its list of offerings. For additional details, please visit https://www.rootsanalysis.com/reports/view_document/subcutaneous-biologics-delivery/314.html The report provides
Glucagon Market Size, Share, Trends, Regional Analysis & Forecast 2027 | Players …
Stratagem Market Insights has announced the addition of the "Glucagon Market Report 2020-2027 Production, Sales And Consumption Status And Prospects Professional Research", The report classifies the global Glucagon Market in a precise manner to offer detailed insights about the aspects responsible for augmenting as well as restraining market growth. The Glucagon Market report is a compilation of first-hand information, qualitative and competitive assessment industry analysts, inputs from industry experts and industry
SMi's Pre-Filled Syringes West Coast conference and exhibition – attendee list …
In just 3 weeks, SMi Group will open its doors to host the next instalment in this year’s PFS conference series, 3rd annual Pre-Filled Syringes West Coast (June 4 – 5, San Diego). Following in the steps of the European and Boston events, the San Diego PFS show will once again gather a truly global audience from not only the USA, but also Belgium, Denmark, France, Germany, UK, Japan and
Active Pharmaceutical Ingredients Market Forecasted to Reach US$ 158.3 Bn by 201 …
PMR in its report, titled “Active Pharmaceutical Ingredient Market – Global Industry Analysis and Forecast, 2016 – 2025” has cited some of the key factors prompting the global sales of API, which include: Higher emphases on the development of novel therapeutics that contain high-potency active pharmaceutical ingredients (HPAPIs). Ramped-up investments from large-scale API manufacturers and contract manufacturers in production of high potency API. The lower cost of labor cost and abundance of raw
Medical Device Leaders Debate on the Future of Combination Products at PFS San D …
SMi Group will welcome the expertise of their growing Pre-Filled Syringes community this June as they invite attendees to share their thoughts at the 2nd annual North American West Coast summit on Pre-Filled Syringes, set to take place on June 5th and 6th in San Diego, California. Entitled “Combination Products - Challenges and Opportunities,” the first interactive panel debate will take place at the end of day one and will be